诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

盘后交易 11-09 19:10:32 EST

163.69

+1.14

+0.70%

盘后164.04

+0.35+0.21%

18:44 EST

最高164.18	最低161.52	成交量231.78万
今开163.73	昨收162.55	日振幅1.64%
总市值3,092亿	流通市值3,018亿	总股本18.89亿
成交额3.78亿	换手率0.13%	流通股本18.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":163.69,"timestamp":1794258000000,"preClose":162.55,"halted":0,"volume":2317771,"hourTrading":{"tag":"盘后","latestPrice":164.04,"preClose":163.69,"latestTime":"18:44 EST","volume":7479,"amount":1223947.17522,"timestamp":1794267862054,"change":0.35,"changeRate":0.002138,"amplitude":0.010522},"delay":0,"changeRate":0.007013226699477,"floatShares":1844000000,"shares":1889000000,"eps":5.24,"marketStatus":"盘后交易","change":1.14,"latestTime":"11-09 19:10:32 EST","open":163.73,"high":164.18,"low":161.52,"amount":378034059.10582,"amplitude":0.016364,"askPrice":164.83,"askSize":50,"bidPrice":160.5,"bidSize":12,"shortable":3,"etf":0,"ttmEps":5.24,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1794272400000},"marketStatusCode":4,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":162.55,"dividendRate":0.028506,"preHourTrading":{"tag":"盘前","latestPrice":163.72,"preClose":162.55,"latestTime":"09:29 EST","volume":20204,"amount":3292705.68384,"timestamp":1794234599220,"change":1.17,"changeRate":0.007198,"amplitude":0.026749},"postHourTrading":{"tag":"盘后","latestPrice":164.04,"preClose":163.69,"latestTime":"18:44 EST","volume":7479,"amount":1223947.17522,"timestamp":1794267862054,"change":0.35,"changeRate":0.002138,"amplitude":0.010522},"volumeRatio":1.277682,"impliedVol":0.2824,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"1106904049","title":"异动解读｜诺华盘前下跌4.04%，Zolgensma肿瘤病例加剧安全性担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1106904049","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106904049?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:02","pubTimestamp":1794214965,"startTime":"0","endTime":"0","summary":"11月9日，诺华盘前下跌4.04%，报163.6255美元/股，成交额41.58万美元。消息面上，公司此前确认其SMA基因疗法Zolgensma上市后累计收到9例肿瘤报告，其中两例已发现载体DNA整合进入患者基因组的证据，市场对基因治疗安全性及后续监管风险的担忧升温。相较于公司此前上调全年核心营业利润预期、以及其他研发与合作进展等已被市场逐步消化，本次股价走弱更贴近最新安全事件扰动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149212324","title":"异动解读｜诺华夜盘下跌3.42%，Zolgensma肿瘤病例引发安全性担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1149212324","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149212324?lang=zh_cn&edition=full","pubTime":"2026-11-09 14:39","pubTimestamp":1794206354,"startTime":"0","endTime":"0","summary":"11月9日，诺华夜盘下跌3.42%，报156.99美元/股，成交额48.4万美元。消息面上，公司此前确认其SMA基因疗法Zolgensma上市后共收到9例肿瘤报告，其中两例已发现载体DNA整合进入患者基因组的证据，市场对基因治疗安全性与后续监管风险的担忧升温。相较之下，诺华此前上调全年核心营业利润预期及终止与BioArctic合作等信息已被市场消化，本次股价走弱更贴近最新安全事件扰动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺华夜盘走低，基因疗法安全性引担忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681844498","title":"关键血脂指标降低78%，却未能减少心梗和中风：诺华放弃潜在重磅心血管药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2681844498","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681844498?lang=zh_cn&edition=full","pubTime":"2026-11-08 14:41","pubTimestamp":1794120113,"startTime":"0","endTime":"0","summary":"11月7日，瑞士制药巨头诺华宣布，基本放弃旗下实验性心血管药物pelacarsen的开发，此前一项历时七年、涉及8322名患者的III期临床试验显示，尽管该药物使患者血液中的脂蛋白〔Lp〕水平平均降低78%，但未能有效减少心脏病发作、中风或心血管死亡事件。医学界此前普遍期待，通过大幅降低这一指标，能够开辟新的心血管疾病预防途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-11-08/doc-inixzany3846576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU0208291251.USD","BK4588","LU0320765489.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4532","BK4007","LU0211331839.USD","IE0009355771.USD","BK4578","IE00B2B36J28.USD","PPH","MEDX","IE0002141913.USD","BK4585","IE00BJJMRZ35.SGD","NVS","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681833541","title":"诺华：中国正成为公司突破性疗法的全球首发市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2681833541","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681833541?lang=zh_cn&edition=full","pubTime":"2026-11-06 11:21","pubTimestamp":1793935276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","NVS","BK4578","LU0211331839.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4588","BK4532","IE00BJT1NW94.SGD","BK4585","PPH","LU0208291251.USD","LU0070302665.USD","IE00B2B36J28.USD","IE0009355771.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181080973","title":"异动解读｜诺华盘中上涨3.07%，近期业绩指引上调后延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1181080973","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181080973?lang=zh_cn&edition=full","pubTime":"2026-11-05 00:25","pubTimestamp":1793809509,"startTime":"0","endTime":"0","summary":"11月5日，诺华盘中上涨3.07%，报164.145美元/股，成交额1.18亿美元。消息面上，公司此前公布三季度调整后每股收益2.46美元，高于市场预期的2.27美元，并将全年核心营业利润预期由低个位数下滑上调至持平至低个位数增长，显示主营产品销售与成本优化对盈利形成支撑。尽管公司11月3日披露终止与BioArctic的合作协议，但市场更关注其近期上调盈利指引、Kisqali与Kesimpta等核心产品增长，以及管理层对长期增长前景维持积极表述。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华业绩指引上调，股价延续强势","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679295224","title":"诺华刚渡过一轮专利悬崖，但新一轮危机已迫在眉睫","url":"https://stock-news.laohu8.com/highlight/detail?id=2679295224","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679295224?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:08","pubTimestamp":1793351280,"startTime":"0","endTime":"0","summary":"诺华刚刚走出史上冲击最猛烈的一轮专利悬崖，三季度盈利能力得到改善。11 月中旬诺华即将公布长期增长战略，这件事也凸显出该药企面临的一大挑战。和奥法木单抗不一样，雷米布鲁替尼旨在调节细胞活性，而非直接清除细胞。一项评估雷米布鲁替尼治疗进展型多发性硬化症效果的临床试验还在推进，预计 2031 年公布结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-30/doc-iniwywts5559864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJJMRZ35.SGD","FHLC","NVS","MEDI","BK4532","BK4007","TMED","PPH","MEDX","BK4588","IE00B2B36J28.USD","BBH","LU0320765489.SGD","BK4585","LU0070302665.USD","LU0208291251.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4578","IE00B4R5TH58.HKD","RSPH","APXH","IE0002141913.USD","PJP","GSKH","JDOC","TRUH","IHE","IYH","PBPH","BBP","FXH","IE00BJT1NW94.SGD","IE0009355771.USD","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169181465","title":"异动解读｜诺华盘中上涨3.34%，上调核心营业利润指引并获券商上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1169181465","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169181465?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:39","pubTimestamp":1793281180,"startTime":"0","endTime":"0","summary":"10月29日，诺华盘中上涨3.34%，报161.95美元/股，成交额3871.72万美元。此次异动的直接催化来自公司上调全年核心营业利润展望，以及券商将目标价由120瑞郎上调至130瑞郎，强化了市场对其基本面韧性的正面解读。公司维持全年净销售额低个位数增长预期，同时将核心营业利润指引由此前低个位数下滑，上调至持平至低个位数增长。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华上调营业利润指引，盘中走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168443909","title":"异动解读｜诺华盘前上涨3.18%，上调核心营业利润指引并获券商上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1168443909","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168443909?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:48","pubTimestamp":1793270926,"startTime":"0","endTime":"0","summary":"10月29日，诺华盘前上涨3.18%，报161.05美元/股，成交额131.19万美元。公司维持全年净销售额低个位数增长预期，同时将核心营业利润展望上调至持平至低个位数增长。尽管公司确认因相关资产计提19亿美元减值，拖累净利润下滑，但Kisqali、Kesimpta等重点产品销售强劲，管理层表示成本节约收益来得更快更多；同时，券商已将其目标价由120瑞郎上调至130瑞郎，进一步强化市场正面解读。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华上调核心营业利润指引，盘前走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678714109","title":"临床试验受挫拖累利润，诺华仍上调业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2678714109","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678714109?lang=zh_cn&edition=full","pubTime":"2026-10-27 23:36","pubTimestamp":1793115360,"startTime":"0","endTime":"0","summary":"内容概要受益于稳健的销售增长以及人工智能带来的成本节约，诺华上调 2026 年核心营业利润指引。尽管近期多项临床试验失利，对这家瑞士制药企业第三季度利润造成冲击，诺华依旧上调全年盈利预期。此次临床试验失败，促使诺华在三季报中对该资产计提 19 亿美元减值损失。受该事件影响，诺华第三季度净利润下滑至 12 亿美元，去年同期为 39.3 亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-27/doc-iniwswnq3670386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","IBBJ","BK4532","BK4588","IE0009355771.USD","LU0211331839.USD","IE00BFTCPJ56.SGD","IBBQ","LU0320765489.SGD","IE00BJJMRZ35.SGD","PPH","BMED","BK4578","NVS","LU0208291251.USD","LU0070302665.USD","BK4007","IE0002141913.USD","PSYK","MEDX","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678201170","title":"诺华首席财务官表示，公司从成本节约计划中获得的收益比预期更多、更快。","url":"https://stock-news.laohu8.com/highlight/detail?id=2678201170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678201170?lang=zh_cn&edition=full","pubTime":"2026-10-27 21:02","pubTimestamp":1793106156,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0208291251.USD","PPH","MEDX","BK4585","LU0211331839.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0070302665.USD","NVS","IE0009355771.USD","BK4007","IE00BJJMRZ35.SGD","BK4588","IE00B2B36J28.USD","BK4532","IE00B4R5TH58.HKD","BK4578","IE00BJT1NW94.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678370122","title":"西班牙百年药企斥资5.3亿元扩建绍兴基地，阿斯利康、礼来、诺华合计抛出超1230亿元投资计划，跨国药企加快布局中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2678370122","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678370122?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:07","pubTimestamp":1793092026,"startTime":"0","endTime":"0","summary":"当地时间10月21日，西班牙制药集团ESTEVE宣布投资超过8000万美元（约合人民币5.3亿元）在浙江绍兴建设新的医药研发生产基地，对原有在华业务进行搬迁、扩建和现代化升级。这家拥有近百年历史的药企2025年收入达8.28亿欧元，旗下合同研发生产（CDMO）业务贡献近六成收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610273909959997.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610273909959997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4578","BK4532","IE00BJT1NW94.SGD","IE0002141913.USD","LU0211331839.USD","NVS","IE00BJJMRZ35.SGD","PPH","BK4007","LU0208291251.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0070302665.USD","LU0320765489.SGD","MEDX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678265951","title":"诺华首席执行官表示，无需采取任何激烈的措施来实现增长。","url":"https://stock-news.laohu8.com/highlight/detail?id=2678265951","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678265951?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:48","pubTimestamp":1793087301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PPH","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4007","LU0211331839.USD","LU0208291251.USD","BK4585","LU0320765489.SGD","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4578","BK4532","LU0070302665.USD","NVS","IE00BFTCPJ56.SGD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678123693","title":"诺华公司公布业绩后，盘前股价预计上涨1.2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2678123693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678123693?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:11","pubTimestamp":1793085089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PPH","MEDX","BK4007","LU0320765489.SGD","BK4532","LU0070302665.USD","IE0002141913.USD","IE0009355771.USD","LU0211331839.USD","NVS","IE00B4R5TH58.HKD","BK4578","IE00BJT1NW94.SGD","BK4585","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678281601","title":"诺华首席执行官：瑞布替尼的销售额仍有可能达到40亿美元或更高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2678281601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678281601?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:58","pubTimestamp":1793084296,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4532","LU0320765489.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE0009355771.USD","NVS","IE00B4R5TH58.HKD","LU0208291251.USD","BK4007","BK4585","PPH","LU0070302665.USD","MEDX","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678514020","title":"诺华制药(NVS.US)Q3营收同比增长4% 长端管线减值拖累净利","url":"https://stock-news.laohu8.com/highlight/detail?id=2678514020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678514020?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:31","pubTimestamp":1793082697,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药周二发布2026年第三季度财报。受研发管线减值及拨备增加影响，IFRS口径净利润为11.96亿美元，同比下降70%，每股收益0.63美元。利润端：核心利润率提升，IFRS利润受一次性项目拖累核心经营利润率达41.6%，同比提升2.3个百分点，主要得益于销售增长。IFRS口径经营利润为18.43亿美元，同比下降59%，经营利润率12.7%，下降19.7个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678140209","title":"诺华制药(NVS.US)Q3营收同比增长4% 长端管线减值拖累净利","url":"https://stock-news.laohu8.com/highlight/detail?id=2678140209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678140209?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:31","pubTimestamp":1793082697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0002141913.USD","BK4588","BK4578","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4585","LU0320765489.SGD","IE00B2B36J28.USD","LU0211331839.USD","LU0208291251.USD","IE00BJT1NW94.SGD","PPH","BK4532","BK4007","IE00BJJMRZ35.SGD","LU0070302665.USD","NVS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678601140","title":"诺华上调全年核心营业利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2678601140","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678601140?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:24","pubTimestamp":1793082240,"startTime":"0","endTime":"0","summary":"瑞士制药巨头诺华周二上调了全年核心营业利润预期。此前，该公司旗下的关键癌症药物和多发性硬化症药物在第三季度需求强劲。该公司目前预计，其核心营业利润将实现低个位数的增长，而此前曾预计会出现低个位数百分比下滑。该公司还维持全年净销售额将实现低个位数增长的预期不变。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-27/doc-iniwrzhq2019209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320765489.SGD","BK4532","LU0211331839.USD","NVS","IE0009355771.USD","IE00B2B36J28.USD","LU0070302665.USD","BK4585","BK4007","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4588","LU0208291251.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","MEDX","PPH","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678147784","title":"诺华股份：Q3核心每股收益2.46美元 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2678147784","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678147784?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:03","pubTimestamp":1793081008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0009355771.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","UDN","BK4578","IE0002141913.USD","LU0211331839.USD","NVS","BK4588","BK4007","IE00BJT1NW94.SGD","BK4532","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","MEDX","PPH","LU0070302665.USD","UUP","IE00BFTCPJ56.SGD","BK4585","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678150292","title":"诺华股价下跌1.6%，此前公布多发性硬化症药物remibrutinib试验数据。","url":"https://stock-news.laohu8.com/highlight/detail?id=2678150292","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678150292?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:02","pubTimestamp":1793001731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0002141913.USD","BK4588","BK4578","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4585","LU0320765489.SGD","IE00B2B36J28.USD","LU0211331839.USD","LU0208291251.USD","IE00BJT1NW94.SGD","PPH","BK4532","BK4007","IE00BJJMRZ35.SGD","LU0070302665.USD","NVS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190598209","title":"异动解读｜诺华盘中下跌3.7%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1190598209","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190598209?lang=zh_cn&edition=full","pubTime":"2026-10-23 23:39","pubTimestamp":1792769951,"startTime":"0","endTime":"0","summary":"10月23日，诺华盘中下跌3.7%，报150.49美元/股，成交额1.83亿美元。此次异动有明确消息面驱动。最新动态显示，瑞银将诺华评级下调至中性，目标价为27元人民币，直接压制市场风险偏好。尽管公司近期披露Kisqali六年期数据显示其在早期乳腺癌中可将死亡风险降低19.1%，且Cosentyx获欧盟批准用于治疗风湿性多肌痛，但财报临近之际，市场仍关注Entresto独占权丧失后销售承压，以及机构对增长前景偏谨慎的判断。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华盘中下跌，瑞银降级引发抛压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.1345},{"period":"3month","weight":0.0398},{"period":"6month","weight":0.1131},{"period":"1year","weight":0.2843},{"period":"ytd","weight":0.179}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立，为股份公司。公司是一家创新医药公司，从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域，包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.004502},{"month":3,"riseRate":0.5,"avgChangeRate":-0.002232},{"month":4,"riseRate":0.692308,"avgChangeRate":0.016763},{"month":5,"riseRate":0.692308,"avgChangeRate":0.0095},{"month":6,"riseRate":0.592593,"avgChangeRate":0.013169},{"month":7,"riseRate":0.666667,"avgChangeRate":0.01085},{"month":8,"riseRate":0.407407,"avgChangeRate":0.000139},{"month":9,"riseRate":0.666667,"avgChangeRate":0.007004},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.007904},{"month":11,"riseRate":0.62963,"avgChangeRate":0.016208},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}